应用Albunex 评估无复流时肌酸磷酸激酶同工酶和肌钙蛋白I 释放动力学变化的实验研究

中国临床药理学与治疗学 ›› 2004, Vol. 9 ›› Issue (5): 514-518.

应用Albunex 评估无复流时肌酸磷酸激酶同工酶和肌钙蛋白I 释放动力学变化的实验研究

陈立新, 王新房¹, 谢明星¹, 朱向明², 吴瑛

暨南大学医学院第二附属医院, 深圳市人民医院超声科, 深圳518020, 广东;
¹华中科技大学同济医学院协和医院超声科, 武汉430022, 湖北;
²皖南医学院弋矶山医院超声科, 芜湖241001, 安徽

收稿日期:2003-11-08 修回日期:2003-12-08 发布日期:2020-11-22

Evaluation of release kinetics of serum creatine kinase isoenzyme MB and cardiac troponin I during no-reflow phenomenon determined by administration of Albunex

CHEN Li-Xin, WANG Xin-Fang², XIE Ming-Xing², ZHU Xiang-Ming², WU Ying

Department of Ultrasonography, Shenzhen People' s Hospital, the Second Teaching Hospital of medical college, Jinan University, Shenzhen 518020, Guangdong, China;
¹Department of Ultrasonography, Union Hospital, Tongji Medical College, HuazhongUniversity of Science and Technology, Wuhan 430022, Hubei, China;
²Department of Ultrasonography, Yijishan Hospital, Wannan Medical College, Wuhu 241001, Anhui, China

Received:2003-11-08 Revised:2003-12-08 Published:2020-11-22
Contact: CHEN Li-Xin, male, doctor, master tutor, engaged in the medical ultrasound in cardiology.Tel:0755-25533018-3351 　E-mail:neost ar84 @yahoo.com.cn

摘要/Abstract

摘要： 目的通过检测肌酸磷酸激酶同工酶MB(CK-MB) 和肌钙蛋白I(cTnI), 了解无复流时CK-MB和cTnI 的变化与心肌微血管损害之间的关系, 分析微血管损伤对CK-MB 和cTnI 释放的影响。方法 19只犬通过制作急性心肌缺血-再灌注动物模型, 采用弹丸式注射声学造影剂Albunex 进行心肌声学造影研究;测定外周循环中CK-MB 和cTnI 在基础状态、60 min 心肌缺血(T₀)、再灌注60 min 时的浓度(T₆₀), 计算再灌注60 min 时其上升斜率(T₆₀-T₀/60) 和相对增加值(T₆0-T₀ /T₀)。结果 CK-MB 和cTnI在心肌缺血60 min 时外周血液浓度明显高于基础状态(P <0.01), 复流组明显高于无复流组(P <0.01);60 min 再灌注时CK-MB 和cTnI 的浓度、上升斜率和相对增加值复流组仍显著高于无复流组(P<0.01 和P <0.001)。结论心肌微血管床的损害影响缺血再灌注心肌酶和结构蛋白的释放。

关键词: Albunex, 无复流现象, 释放动力学, 肌酸磷酸激酶同工酶MB, 肌钙蛋白I

Abstract: AIM: To validate the relationship between the release kinetics of serum creatine kinase isoenzyme MB (CK-MB) and cardiac tropnin I (cTnI) and myocardial microvascular impairment during the development of no-reflow phenomenon by measurement of serum CK-MB and cTnI in combination with administration of Albunex. METHODS: 19 dogs underwent 60 min myocardial ischemia, followed by reperfusion of 60 min (n=6), 120 min (n=6) and 180 min (n=7), respectively.Myocardial contrast echocardiography (MCE) was performed by a bolus injection of Albunex.The measurement of peripheral blood concentrations of CK-MB and cTnI at baseline, 60 min ischemia (T0) and 60 min reperfusion (T60) were initiated, and then the increase slope (T60-T0 60) and relative increase value (T60-T0/T0) were calculated at 60 min reperfusion. RESULTS: The concentrations of serum CK-MB and cTnI were markedly higher at 60 min myocardial ischemia than those at baseline (P <0.01).At 60 min reperfusion, a significant difference in the levels of CK-MB and cTnI was observed between ref low group and no-reflow group (P < 0.01).There was a marked difference in the levels of CK-MB and cTnI between reflow group and no-reflow group, too (P <0.01).An extremely significant difference in the increase slope and relative increase value at 60 min reperfusion between two groups was found (P < 0.001). CONCLUSION: These findings show that damaged microvarculature may profoundly influence the release kinetics of serum CK-MB and cTnI.

Key words: Albunex, no-reflow phenomenon, release kinetics, creatine kinase isoenzyme MB, cardiac tropnin I

中图分类号:

陈立新, 王新房, 谢明星, 朱向明, 吴瑛. 应用Albunex 评估无复流时肌酸磷酸激酶同工酶和肌钙蛋白I 释放动力学变化的实验研究[J]. 中国临床药理学与治疗学, 2004, 9(5): 514-518.

CHEN Li-Xin, WANG Xin-Fang1, XIE Ming-Xing1, ZHU Xiang-Ming2, WU Ying. Evaluation of release kinetics of serum creatine kinase isoenzyme MB and cardiac troponin I during no-reflow phenomenon determined by administration of Albunex[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2004, 9(5): 514-518.

参考文献

1 Yang TS.Experimental diagnosis of coronary heart disease[M]. Beijing:Scientific and Technical Documents Publishing House, 2002:275-87
2 CogginsMP, Sklenar J, Le DE, Wei K, Lindner JR, Kaul S. Noninvasive prediction of ultimate infarct size at the time of acute coronary occlusion based on the extent and magnitude of collateral-derived myocardial blood flow[J].Circulation, 2001; 104(20):2471-7
3 Reffelmann T, Kloner RA.The “no-reflow” phenomenon:basic science and clinical correlates[J].Heart, 2002;87(2):162-8
4 Adamas JE, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH.Cardiac troponin I:a markerwith high specificity for cardiac injury[J].Circulation, 1993;88(1):101-6
5 Bodor GS, Porter S, Landt Y, Ladenson JH.The development of monoclonal antibodies and an assay for cardiac troponin I with preliminary results in suspected myocardial infarction[J].Clin Chem, 1992;38(11):2203-14
6 Falahati A, Sharkey SW, Christensen D, McCoy M, Miller EA, Mary AnnM, et al.Implementation of serum cardiac troponin I as marker for detection of acute myocardial infarction [J].Am Heart J, 1999;137(2):332-7
7 Tanasijevic MJ, Antman EM.Diagnostic performance of cardiac troponin I in suspected acute myocardial infarction:Implications for clinicians[J].Am Heart J, 1999;137(2):203-6
8 Cardiovascular Association of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology, Editorial Board of Chinese Journal of Circulation.Diagnosis and therapeutic guideline for acute myocardial infarction[J].Chin J Cardiol, 2001; 29(12):710-25
9 Mair J.Tissue release of cardiac markers:from physiology to clinical applications[J].Clin Chem Lab Med, 1999;37(11-12):1077-84
10 Jiang YQ, Liu CZ, Zhu GY.Modern Cardiology of Coronary Artery Disease[M].Beijing:People Military Medical Publishing House, 2001:529-39
11 Kloner RA, Ganote CE, Jennings RB.The “ no-reflow” phenomenon after temporary coronary occlusion in the dog[J].J Clin Invest, 1974;54(6):1496-508
12 Laperche T, Steg PG, Dehoux M, Benessiano J, Grollier G, Aliot E, et al.A study of biochemical markers of reperfusion early after thrombolysis for acute myocardial infarction[J].Circulation, 1995;92(8):2079-86
13 Iwakura K, Ito H, Takiuchi S, Taniyama Y, Nakatsuchi Y, Negoro S, et al.Alteration in the coronary blood flow velocity pattern in patients with no-reflow and reperfused acute myocardial infarction[J].Circulation, 1996;94(6):1269-75

[1]	杨胜, 王德国. 沙库巴曲缬沙坦联合达格列净治疗射血分数减低型心力衰竭疗效及对血清cTnⅠ、BNP水平的影响[J]. 中国临床药理学与治疗学, 2022, 27(9): 1010-1015.
[2]	李祥东, 王安才. NT-proBNP、cTnI、H-FABP对呼吸困难鉴别诊断及预后判断的价值[J]. 中国临床药理学与治疗学, 2015, 20(5): 562-566.
[3]	陈立新, 王新房, 谢明星, 朱向明, 吴瑛. 应用Albunex 结合经胸多普勒超声评估无复流时冠脉血流速度模式变化的实验研究[J]. 中国临床药理学与治疗学, 2005, 10(3): 270-275.